<DOC>
	<DOCNO>NCT00826449</DOCNO>
	<brief_summary>The goal Phase I portion study find high tolerable dose combination dasatinib erlotinib hydrochloride give patient advance solid tumor . The goal Phase II portion study learn combination effective give patient non-small cell lung cancer . The safety combination study phase .</brief_summary>
	<brief_title>Dasatinib Erlotinib Non-Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description>The Study Drugs : Dasatinib design decrease activity one proteins responsible uncontrolled growth tumor cell . This may cause tumor cell die . Erlotinib hydrochloride design block activity protein find surface many tumor cell . Blocking protein may control tumor growth survival . This may stop tumor grow . Study Groups : If find eligible participate study , assign study group base join study . Up 6 group 3-6 participant enrol Phase I portion study , 35 participant enrol Phase II . If enrolled Phase I portion , dose dasatinib receive depend join study . The first group participant receive low dose level dasatinib . Each new group receive high dose dasatinib group , intolerable side effect see . If intolerable side effect see , next group participant may receive dose level low dose level . This continue high tolerable dose dasatinib find . If enrol Phase II portion , receive high tolerate dose level dasatinib find Phase I portion . All participant receive dose level erlotinib hydrochloride . If doctor think need , dose level may lower . Study Drug Administration : If Phase I , Day -3 Cycle 1 ( 3 day first dose study drug ) , take erlotinib hydrochloride mouth . On Days 1-19 Cycle 1 , take dasatinib erlotinib hydrochloride mouth day . On Days 20 21 Cycle 1 , take dasatinib mouth day . Every day Cycles 2 beyond , take dasatinib erlotinib hydrochloride mouth day . If Phase II , every day take dasatinib erlotinib hydrochloride mouth day . Each cycle 21 day . Erlotinib hydrochloride dasatinib take together time every day . The tablet must swallow whole may break . The tablet take 1 cup ( 8 ounce ) water . Dasatinib erlotinib hydrochloride take 1 hour 2 hour meal drug , take grapefruit juice . The entire dose must take 1 time . If vomit within 30 minute swallow tablet , dose may replace tablet see count . If currently take St. John 's Wort , stop take least 5 day take dasatinib . Study Visits : At Week 1 Cycle 1 , vital sign weight measure . At end Week 3 every cycle , follow test procedure perform : - You physical exam , include measurement vital sign weight . - You performance status evaluation . - Blood ( 1 tablespoon ) drawn routine test - The amount oxygen blood measure pulse oximeter . - You chest x-ray check status disease . - You ask experienced side effect list drug may take . - Women able become pregnant must negative blood ( 1-2 teaspoon ) urine pregnancy test . At end Week 3 Cycles 1 3 , also ECG . At end Week 3 every cycle ( Cycles 2 , 4 , 6 , ) , also chest CT scan whole body PET/CT ( necessary ) check status disease . Phase I PK Testing : If Phase I , blood ( 2 teaspoon time ) drawn PK testing . - On Day -3 Cycle 1 , blood drawn 5 different time . - On Days -2 , -1 , 1 Cycle 1 , blood drawn 1 time . - On Day 19 Cycle 1 , blood drawn 5 time . - On Days 20 , 21 , 22 Cycle 1 , blood drawn 1 time . Length Study : You may stay study long benefitting . You take study experience intolerable side effect disease get bad . End-of-Study Visit : At end study participation , end-of-study visit . At visit , follow test procedure perform : - You physical exam , include measurement vital sign weight . - You performance status evaluation . - Blood ( 1 tablespoon ) drawn routine test . - The amount oxygen blood measure . - You chest x-ray check status disease . - You ECG . If take study due unacceptable side effect , call ask side effect side effect get good becomes stable . Long-Term Follow-Up : After end-of-study visit , contact every 3-4 month 1 year collect information . You ( family member designees ) may contact telephone clinic visit . If call , take 5 minute . This investigational study . Dasatinib FDA approve commercially available treatment acute lymphoid chronic myeloid leukemia . Erlotinib hydrochloride FDA approve commercially available treatment non-small cell lung cancer . The use combination study investigational . Up 59 patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>1 . Advanced malignancy appropriate systemic therapy without curative intent . 2 . Patients must provide verbal write informed consent indicate aware investigational nature study . Parental consent patient assent require aged 1617 . 3 . Patients must least 16 year age . 4 . Eastern Cooperative Oncology Group ( ECOG ) performance status 01 . 5 . Adequate hematologic , hepatic , renal function follow : creatinine &lt; 1.5 x institutional upper limit normal ( ULN ) , total bilirubin &lt; 2.0 x ULN , AST ALT &lt; 2.5 x ULN , absolute granulocyte &gt; /= 1500/mm^3 ; platelet &gt; /= 75,000 mm^3 ; hemoglobin &gt; /= 10 g/dL . 6 . Serum potassium , magnesium , phosphate within institutional limit normal . Patients low potassium , phosphate , magnesium level may replete allow protocol entry . 7 . Serum calcium &gt; /= institutional limit normal . Patients low calcium level may replete allow protocol entry . 8 . Ability take oral medication ( dasatinib erlotinib must swallow whole ) 9 . Patientsboth males &amp; femalesw/reproductive potential must agree use adequate method contraception include hormonal contraceptive ( birth control pill , injection , implant ) , intrauterine device ( IUD ) , barrier contraceptive spermicide , and/or abstinence throughout study &amp; least 4 wks study drug stop . Females w/ reproductive childbearing potential include female experienced menarche &amp; undergone successful surgical sterilization ( hysterectomy , bilateral tubal ligation bilateral oophorectomy ) postmenopausal 10 . Continued Inclusion # 9 [ define amenorrhea &gt; /=12 consecutive mths ; woman hormone replacement therapy ( HRT ) w/ document serum follicle stimulate hormone ( FSH ) level &gt; 35 milliInternational unit ( mIU ) /mL ] . Prior study enrollment , woman childbearing potential must advise importance avoid pregnancy trial participation potential risk factor unintentional pregnancy . 11 . Women childbearing potential must provide negative pregnancy test ( serum urine ) within 72 hour prior start study drug administration . 12 . Asymptomatic brain metastasis prior cranial irradiation resection acceptable bleeding , midline shift , need steroid anticonvulsant . Asymptomatic brain metastasis without prior treatment acceptable large lesion le 7 mm diameter , bleeding , midline shift , need steroid anticonvulsant . 13 . Patient agree discontinue St. Johns Wort least 5 day start dasatinib erlotinib . 14 . Patient agree IV bisphosphonates withhold first 8 week dasatinib therapy due risk hypocalcemia . 15 . The patient 's O^2 saturation must &gt; 92 % room air . 16 . ( Phase II ) Patient never receive prior therapy dasatinib , erlotinib , another epidermal growth factor receptor ( EGFR ) Src family kinase ( SFK ) inhibitor . 17 . ( Phase I ) Histological unequivocal cytological proof solid tumor malignancy . 18 . ( Phase I ) At least one prior systemic chemotherapy biological therapy recurrent metastatic solid tumor ( i.e. , protocol therapy must administer second line great ) , ) , except standard experimental systemic therapy available . If effective systemic agent available first line therapy , patient may enrol phase I first line therapy . 19 . ( Phase I ) Prior radiotherapy permit ( see exclusion criterion 4 detail unallowable radiotherapy ) . 20 . ( Phase II ) Histological unequivocal cytological proof NSCLC . 21 . ( Phase II ) NSCLC appropriate systemic therapy without curative intent : Stage IV , Stage IIIB pleural effusion , incurable recurrent disease surgery radiotherapy . 22 . ( Phase II ) Zero one line prior systemic therapy recurrent metastatic NSCLC . Prior adjuvant chemotherapy adjuvant biologic therapy NSCLC include line prior therapy complete great 3 month prior recurrence , provide patient never receive EGFR SFK inhibitor . 23 . ( Phase II ) Measurable disease define Response Evaluation Criteria Solid Tumors ( RECIST ) criterion . 24 . ( Phase II ) Availability tumor tissue least adequate EGFR mutational analysis . This come preexisting paraffin block ( diagnostic biopsy surgical resection ) patient may undergo biopsy research purpose . 25 . ( Phase II ) Prior radiotherapy permit long measurable disease outside radiotherapy port OR clearly recurrent grow within radiotherapy port ( see exclusion criterion 2 detail unallowable radiotherapy ) . 1 . Women pregnant , breastfeeding , childbearing potential unwilling/unable use acceptable method contraception entire study period least 4 week cessation study drug . All woman childbearing potential must negative pregnancy test prior first receive protocol therapy . If pregnancy test positive , patient must receive dasatinib erlotinib , must enrol study 2 . Radiotherapy rib , sternum , pelvis , vertebra skull within 4 week prior enter study . ( If none axial skeletal area include radiotherapy field , patient may receive palliative radiotherapy long bone provide end least 2 week prior initiation dasatiniberlotinib therapy . ) 3 . Patients follow cardiac problem exclude : ( ) Uncontrolled angina , congestive heart failure , myocardial infarction within previous 6 month ; ( b ) Diagnosed congenital long QT syndrome ; ( c ) Any history clinically significant ventricular arrhythmia ( ventricular tachycardia , ventricular fibrillation , Torsades de pointes ) ; ( ) Prolonged [ 1 ] correct QT interval ( QTc ) interval preentry electrocardiogram ( &gt; 450 msec woman &gt; 440 msec men ) . If automate reading prolong , ECG manually read . 4 . Continued Exclusion # 4 : ( e ) Any history second third degree heart block unless currently pacemaker ; ( f ) Heart rate &lt; 50 / minute preentry electrocardiogram ; ( g ) Uncontrolled hypertension define systolic blood pressure &gt; 150 diastolic &gt; 100 ; ( h ) Subjects hypokalemia hypomagnesemia correct prior dasatinib administration . 5 . Patients pericardial effusion &gt; grade 1 ( Common Toxicity Criteria Adverse Effects ( CTCAE ) v3.0 ) . 6 . Patients pleural effusion &gt; grade 2 ( CTCAE v3.0 ) . A grade 3 pleural effusion manage thoracentesis indwell catheter allowable long supplemental oxygen require . 7 . Patients condition impairs ability swallow , retain , absorb dasatinib erlotinib tablet exclude . This include condition result inability take oral medication , requirement IV alimentation , prior surgical procedure result chronic malabsorption , active peptic ulcer disease . 8 . Patients &gt; grade 2 neuropathy 9 . Patients history pulmonary fibrosis ( radiated field ) . 10 . Patients inflammatory bowel disease uncontrolled chronic diarrhea . 11 . Patients history significant bleeding disorder unrelated cancer , include : ( ) Diagnosed congenital bleeding disorder ( e.g. , von Willebrand 's disease ) ; ( b ) Diagnosed acquire bleed disorder within one year ( e.g. , acquire antifactor VIII antibody ) ; ( c ) Ongoing recent ( &lt; /= 3 month ) significant gastrointestinal bleeding , define clinically evident hematemesis hematochezia require therapeutic intervention . 12 . Known HIVpositive patient ineligible potential pharmacokinetic interaction dasatinib antiretroviral therapy . In addition , patient increase risk lethal infection treat marrowsuppressive therapy . 13 . Pts currently receive follow medication exclude : ( ) Any concurrent systemic anticancer therapy ; ( b ) Any concurrent investigational agent ( c ) Category I drug generally accept risk cause Torsades de Pointes include : ( Pts must discontinue drug 7 day prior start dasatinib ) : i. quinidine , procainamide , disopyramide ; ii . amiodarone , sotalol , ibutilide , dofetilide ; iii . erythromycin , clarithromycin ; iv . chlorpromazine , haloperidol , mesoridazine , thioridazine , pimozide 14 . Continued Exclusion # 14 : v.cisapride , bepridil , droperidol , methadone , arsenic , chloroquine , domperidone , halofantrine , levomethadyl , pentamidine , sparfloxacin , lidoflazine ; ( ) The concomitant use H2 blocker proton pump inhibitor w/ dasatinib recommended.The use antacid consider place H2 blocker proton pump inhibitor pts receive dasatinib therapy.If antacid therapy need , antacid dose administer least 2 hour prior 2 hour dose dasatinib . 15 . Continued Exclusion # 15 : ( e ) Pt may receive prohibited CYP3A4 inhibitor Potent inhibitor CYP3A4 prohibit study ; medication , washout period 7 day require prior start dasatinib . Potent CYP3A4 inhibitor include : · itraconazole , ketoconazole , miconazole , voriconazole ; amprenavir , atazanavir , fosamprenavir , indinavir , nelfinavir , ritonavir ; ciprofloxacin , clarithromycin , diclofenac , doxycycline , enoxacin , imatinib , isoniazid , ketamine nefazodone , nicardipine , propofol , quinidine , telithromycin . ( f ) St.Johns Wort 16 . The patient receive prior investigational therapy , chemotherapy , radiotherapy , major surgery within 3 week initiate study drug .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Advanced Solid Tumors</keyword>
	<keyword>Advanced Cancer</keyword>
	<keyword>Non-Small Cell Lung Cancer</keyword>
	<keyword>NSCLC</keyword>
	<keyword>Solid Tumor Malignancy</keyword>
	<keyword>Dasatinib</keyword>
	<keyword>BMS-354825</keyword>
	<keyword>Sprycel®</keyword>
	<keyword>Erlotinib</keyword>
	<keyword>Erlotinib hydrochloride</keyword>
	<keyword>Tarceva</keyword>
	<keyword>OSI-774</keyword>
</DOC>